Team:Evry

From 2013.igem.org

(Difference between revisions)
Line 38: Line 38:
<p>
<p>
-
E. van der Kouwe, G. Mercy, B. Baudu, A. Chhun, F. Amiot, G. Guillocheau, L. Le Goff, H. Léger, L. Ujéda, W. Rostain, C. Pauthenier, T. Cerisy, P. Parutto, A. Jaramillo, A. Tolonen and N. Pollet
+
E. van der Kouwe<sup>1, 2</sup>, G. Mercy<sup>3</sup>, B. Baudu<sup>4</sup>, A. Chhun<sup>1</sup>, F. Amiot<sup>1</sup>, G. Guillocheau<sup>1</sup>, L. Le Goff<sup>5</sup>, H. Léger<sup>5</sup>, L. Ujéda<sup>6</sup>, W. Rostain, C. Pauthenier, T. Cerisy, P. Parutto, A. Jaramillo, A. Tolonen and N. Pollet
</p>
</p>
Line 58: Line 58:
<p>
<p>
-
<sup>1</sup>
+
<sup>1</sup>Université Evry Val d'Essonne
</p>
</p>
<p>
<p>
-
<sup>2</sup>
+
<sup>2</sup>Faculté de Pharmacie de Lyon
</p>
</p>
<p>
<p>
-
<sup>3</sup>
+
<sup>3</sup>Sup'Biotech Paris
</p>
</p>
<p>
<p>
-
<sup>4</sup>
+
<sup>4</sup>AgroParisTech
</p>
</p>
<p>
<p>
-
<sup>5</sup>
+
<sup>5</sup>Ecole Nationale Supérieure d'Informatique pour l'Industrie et l'Entreprise
</p>
</p>
<p>
<p>
-
<sup>6</sup>
+
<sup>6</sup>Sciences Po Paris
</p>
</p>

Revision as of 11:00, 9 August 2013

Iron coli project

Welcome to the Evry team Home Page

Title

Iron coli Project

Authors

E. van der Kouwe1, 2, G. Mercy3, B. Baudu4, A. Chhun1, F. Amiot1, G. Guillocheau1, L. Le Goff5, H. Léger5, L. Ujéda6, W. Rostain, C. Pauthenier, T. Cerisy, P. Parutto, A. Jaramillo, A. Tolonen and N. Pollet

Abstract

This year, our project focuses on hematological disorders. More specifically, we focus on diseases that are subsequent to an iron overload such as hemochromatosis and thalassemia. For hereditary hemochromatosis, the symptoms are due to the overabsorption of iron from the duodenum by the mutation of the HFE protein. However, in case of thalassemia, patients excessively absorb iron because of a subsequent metabolic perturbation.

Nowadays, the iron overload is mainly treated by bloodlettings for hemochromatosic patients but cannot be extended to thalassemic patients who suffer from anaemia. The aim of our project is to prevent the intestinal absorption of iron, thus acting directly at the source.

Using the Ferric Uptake Regulation (FUR) system that controls siderophore biosynthesis (iron chelator), we engineer Escherichia coli in order to produce these siderophores in response of high concentrations of iron. To reduce the patient's iron absorption, our bacteria will be placed in a capsule and will be ingested during a meal. Once it will arrive in the duodenum, our bacteria will produce the siderophore at their full potential and chelate the iron.

Affiliations

1Université Evry Val d'Essonne

2Faculté de Pharmacie de Lyon

3Sup'Biotech Paris

4AgroParisTech

5Ecole Nationale Supérieure d'Informatique pour l'Industrie et l'Entreprise

6Sciences Po Paris